Apexigen, Inc

Founded in 1997, ChemoCentryx is a clinical-based pharmaceutical company that discovers and develops orally-administered small molecule therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. It has developed EnabaLink, which is a drug recovery technology that is designed to accelerate productive drug recovery program. The company also conducts preclinical evaluation of a series of anticancer compounds that target the CXCR7 chemokine receptor. ChemoCentryx evaluates a series of compounds that target the C5a chemo-attractant receptor to treat age-related macular degeneration, rheumatoid arthritis and systemic lupus erythematosus and other disorders. It has entered into a strategic alliance with Glaxo Group, which is an affiliate of GlaxoSmithKline. ChemoCentryx maintains its headquarters in Mountain View, Calif.

Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company based in San Carlos, CA, specializing in the discovery and development of optimized immunotherapeutics for cancer and autoimmune diseases. Their core technology integrates structure-guided cytokine evolution and target-based protein evolution, enabling the development of fully optimized cytokine fusions with superior therapeutic potential. With a focus on improving the lives of patients, Anwita Biosciences is advancing their product pipeline of improved cytokines and tumor-targeting antibody drug conjugates, including their lead product, Exenokine-21, which has been accepted for clinical studies by regulatory authorities in China and the US. Utilizing their expertise in cancer immunotherapy, bioinformatics, and target-based protein evolution, Anwita Biosciences aims to deliver transformative treatment options for patients with cancer and autoimmune diseases. Their unique product portfolio includes half-life extended cytokines, immune cell- or tumor cell-targeting cytokines, and bi-functional cytokines. Through ongoing clinical trials and partnerships, Anwita Biosciences is dedicated to developing novel immune therapies that have the potential to significantly impact the field of oncology and autoimmune disease treatment.Generated from the website

Vifor Pharma is a global leader in iron deficiency and nephrology, dedicated to improving the lives of patients with severe and chronic diseases. With a strong presence worldwide, they strive to provide innovative therapies and solutions for those suffering from chronic kidney disease. Committed to transparency and patient well-being, Vifor Pharma conducts investigator-initiated studies and offers a range of nephrology products to address the specific needs of patients. Their mission is to help individuals lead better, healthier lives by providing effective treatments and support for chronic conditions.Generated from the website